Instrument Inactif

Communiqués NeoStem Inc NYSE

Actions

NBS

US6406503051

Recherche biotechnologique et médicale

Cours en clôture NYSE Autres places de cotation
- ^USD	-

06/08	Lisata Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
04/08	Lisata Therapeutics, Inc. poursuit l'évaluation d'alternatives stratégiques pour accroître la valeur actionnariale	CI

Communiqués

04/08	Lisata Therapeutics Provides Update Following Termination of Merger Agreement	GL
15/06	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)	NE
10/06	Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.	GL
12/03	Lisata Therapeutics : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
07/03	Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.	GL
27/01	Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide	GL
21/01	Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer	GL
06/11	Lisata Therapeutics : Earnings Release (lisata therapeutics reports third quarter 2025 financial results)	PU
06/11	Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	GL
06/11	Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’	GL
04/11	Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent	GL
30/10/25	Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025	GL
30/10/25	Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025	AQ
13/10/25	Lisata Therapeutics to Present at LD Micro Main Event XIX	NE
08/10/25	Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement	GL
08/10/25	Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement	AQ
29/09/25	Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial	GL
29/09/25	Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial	AQ
02/09/25	Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference	GL
07/08/25	Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update	GL
31/07/25	Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025	GL
17/07/25	Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update	GL
15/07/25	Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide	GL
15/07/25	Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide	AQ
26/06/25	Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer	GL